帕布昔利布是辉瑞公司开发的ER阳性和HER2阴性乳腺癌的药物。它是细胞周期蛋白依赖性激酶CDK4和CDK6的选择性抑制剂。
6-acetyl-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one
6-bromo-8-cyclopentyl-5-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-7(8H)-one
